Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Titre officiel

A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Sommaire:

Cet essai de phase I porte sur les effets secondaires et la meilleure dose de transducteur de l’inhibiteur de l’activité régulée de CREB 1/2 (TORC1/2), soit l’INK128, administrée en association avec l’inhibiteur du récepteur de facteur de croissance épidermique (EGFR), soit l’AZD9291, dans le cadre d’un traitement de patients atteints d’un cancer du poumon non à petites cellules présentant une mutation du gène de l’EGFR, qui s’est propagé vers d’autres régions de l’organisme (stade avancé) et qui a progressé après un traitement par un inhibiteur de la tyrosine kinase de l’EGFR. L’inhibiteur du TORC1/2, soit l’INK128, et l’inhibiteur de l’EGFR, soit l’AZD9291, peuvent stopper la croissance des cellules tumorales en bloquant certaines enzymes nécessaires à la croissance cellulaire.

Description de l'essai

Primary Outcome:

• Maximum tolerated dose of sapanisertib in combination with osimertinib in patients with EGFRmutant (m) non-small cell lung cancer (NSCLC)
• Dose-limiting toxicity (DLT) of sapanisertib in combination with osimertinib in patients with EGFRm NSCLC

Secondary Outcome:

• Non-DLTs associated with the administration of sapanisertib and osimertinib
• Pharmacokinetic (PK) profiles of sapanisertib in combination with osimertinib
• Response rate
• Disease control rate
• Progression free survival
• Response rate of patients with T790M- NSCLC in an expansion cohort
• Disease control rate of patients with T790M- NSCLC in an expansion cohort
• Progression free survival of patients with T790M- NSCLC in an expansion cohort
• Biomarkers of response and resistance to the combination, explored by studying baseline biopsies, resistance biopsies, and serial plasma deoxyribonucleic acid specimens

PRIMARY OBJECTIVES:
I. To determine the safety and recommended phase II dose (RP2D) of sapanisertib (MLN0128) (TAK-228) in combination with osimertinib (AZD9291) in patients with advanced epidermal growth factor receptor mutation positive (EGFRm) non-small cell lung cancer (NSCLC) and who are resistant to previous EGFR-tyrosine kinase inhibitor (TKI) therapy. (Dose escalation phase) II. To evaluate the safety and preliminary efficacy of MLN0128 (TAK-228) in combination with osimertinib (AZD9291) in patients with advanced EGFRm NSCLC who are resistant to previous EGFR-TKI therapy with first line osimertinib. (Dose expansion phase) SECONDARY OBJECTIVES:
I. To evaluate pharmacokinetic profiles of MLN0128 (TAK-228) in combination with osimertinib (AZD9291). II. To evaluate the response rate, disease control rate and progression free survival of the combination. III. To explore biomarkers of response and resistance to the combination by studying baseline biopsies, resistance biopsies, and serial plasma deoxyribonucleic acid (DNA) specimens. OUTLINE:

This is a dose-escalation study of sapanisertib. Patients receive sapanisertib orally (PO) once daily (QD) on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26 (day 1 is omitted in cycle 1). Patients also receive osimertinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 30 days, and then every 8 weeks thereafter.

Voir cet essai sur ClinicalTrials.gov